Literature DB >> 22379171

Risk factors for chronic thromboembolic pulmonary hypertension.

N H Kim1, I M Lang.   

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension caused by obstruction and vascular remodelling of pulmonary arteries following pulmonary embolism. Risk factors that predispose patients to CTEPH include the size of the initial thrombus and numerous associated host or medical conditions. Haemostatic risk factors include elevated levels of factor VIII and phospholipid antibodies or intrinsic abnormalities in fibrinogen. Medical conditions that are associated with an increased risk of CTEPH include a history of splenectomy, cancer, ventriculoatrial shunt, chronic inflammatory disease, antiphospholipid antibodies and hypothyroidism. Although CTEPH is potentially curable by pulmonary endarterectomy (PEA), up to 40% of patients evaluated for PEA may be denied surgery depending on the level of surgical experience and disease accessibility after pre-operative assessment. Furthermore, an estimated 10-15% of patients are at risk for residual pulmonary hypertension following PEA surgery, due to significant concomitant small-vessel disease. However, pre-operative identification of small-vessel involvement remains a challenge. The current medications effective in the treatment of pulmonary arterial hypertension have not demonstrated efficacy in CTEPH. Accordingly, identification of CTEPH, followed by early referral for evaluation and treatment by an experienced PEA centre, is recommended.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22379171     DOI: 10.1183/09059180.00009111

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  24 in total

1.  The link between chronic thromboembolic pulmonary hypertension and sarcoidosis: association or visual masquerade?

Authors:  Rajive Tandon; Robert P Baughman; Janice Stanley; Ali A Khan
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Characterization of biological pathways associated with a 1.37 Mbp genomic region protective of hypertension in Dahl S rats.

Authors:  Allen W Cowley; Carol Moreno; Howard J Jacob; Christine B Peterson; Francesco C Stingo; Kwang Woo Ahn; Pengyuan Liu; Marina Vannucci; Purushottam W Laud; Prajwal Reddy; Jozef Lazar; Louise Evans; Chun Yang; Theresa Kurth; Mingyu Liang
Journal:  Physiol Genomics       Date:  2014-04-08       Impact factor: 3.107

3.  Neutrophil/Lymphocyte Ratio Can Predict Postoperative Mortality in Patients with Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Mehmed Yanartas; Mehmet Emin Kalkan; Akin Arslan; Serpil Gezer Tas; Cengiz Koksal; Nural Bekiroglu; Bedrettin Yildizeli
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-03-09       Impact factor: 1.520

Review 4.  Pulmonary hypertension survival effects and treatment options in cystic fibrosis.

Authors:  Adriano R Tonelli
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

5.  Acute pulmonary hypertension caused by tumor embolism: a report of two cases.

Authors:  Caroline Mury; Antoine G Schneider; Antoine Nobile; Samuel Rotman; Lucas Liaudet
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

6.  The effects of obesity on venous thromboembolism: A review.

Authors:  Genyan Yang; Christine De Staercke; W Craig Hooper
Journal:  Open J Prev Med       Date:  2012-11

Review 7.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

8.  Outpatient or inpatient treatment for acute pulmonary embolism: a retrospective cohort study of 439 consecutive patients.

Authors:  Sebastian Werth; Virginia Kamvissi; Thoralf Stange; Eberhard Kuhlisch; Norbert Weiss; Jan Beyer-Westendorf
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

Review 9.  Balloon Pulmonary Angioplasty in Patients With Thromboembolic Pulmonary Hypertension.

Authors:  Panagiotis Karyofyllis; Varvara Papadopoulou; Vassilis Voudris; Hiromi Matsubara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-02-24

10.  Chronic thromboembolic pulmonary hypertension secondary to implantable cardioverter defibrillator lead thrombus in a patient with Brugada syndrome: a rare complication requiring a multidisciplinary approach.

Authors:  Sofia Alegria; Filipa Ferreira; Débora Repolho; Maria José Loureiro
Journal:  BMJ Case Rep       Date:  2020-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.